Subscribe today and get credible, unbiased information from disease experts sent straight to your phone or inbox.
Jack West, MD discussed the 3-year, updated results of the Checkmate 227 trial in 1L patients with advanced metastatic NSCLC treated with either nivolumab + ipilimumab OR chemotherapy alone. Data focuses on overall survival in different subsets of patients at three years.
“Nivo/Ipi is certainly an encouraging, reasonable option that may have a particular advantage in its long-term efficacy.
Subscribe today and get credible, unbiased information from disease experts sent straight to your phone or inbox.
Contact us to join our network, learn more about our educational offerings, or inquire about joining our faculty. We are your source for up-to-date clinical information.
GET IN TOUCH
Dr. West is an Associate Clinical Professor in Medical Oncology, a specialist in thoracic
oncology, and serves as Executive Director of AccessHope remote consult services at City of Hope Comprehensive Cancer Center.
Dr. West received an MPhil in Experimental Biology from Cambridge University on a
Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical
School, where Dr. West also conducted research as a Howard Hughes Medical Student
Fellow. His postdoctoral training included an internship and residency in internal
medicine at the Harvard-affiliated Brigham and Women’s Hospital Boston, MA, followed
by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/
University of Washington in Seattle, WA. In late, 2002, he moved to Swedish Cancer Institute in Seattle, where he served for over 16 years as Medical Director of the Thoracic Oncology Program, overseeing a broad array of clinical care and research responsibilities.
In early 2019, he moved to Los Angeles area to dedicate his focus on innovative approaches to delivering sub-specialist expertise across a broader geography, using tools such as remote case reviews as a clinical leader of the new enterprise from City of Hope, known as AccessHope.
He has authored dozens of papers and chairs several CME programs and symposia
internationally on thoracic oncology, novel educational approaches, and social media in
cancer care. In addition to these activities, he is the Founder & President of Global Resource for
Advancing Cancer Education (GRACE); Web Editor for JAMA Oncology; regular
correspondent for Medscape; and contributing author and section editor in Lung Cancer
for UpToDate.